Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Protara Therapeutics (TARA) Enterprise Value (2016 - 2026)

Protara Therapeutics' Enterprise Value history spans 14 years, with the latest figure at -$135.8 million for Q1 2026.

  • Quarterly Enterprise Value fell 9.19% to -$135.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$135.8 million through Mar 2026, down 9.19% year-over-year, with the annual reading at -$155.6 million for FY2025, 8.65% up from the prior year.
  • Enterprise Value came in at -$135.8 million for Q1 2026, up from -$155.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$55.2 million in Q1 2024 to a low of -$170.3 million in Q4 2024.
  • The 5-year median for Enterprise Value is -$89.6 million (2024), against an average of -$102.4 million.
  • Year-over-year, Enterprise Value soared 52.48% in 2022 and then crashed 159.67% in 2024.
  • Protara Therapeutics' Enterprise Value stood at -$84.4 million in 2022, then increased by 22.27% to -$65.6 million in 2023, then plummeted by 159.67% to -$170.3 million in 2024, then grew by 8.65% to -$155.6 million in 2025, then rose by 12.71% to -$135.8 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Enterprise Value are -$135.8 million (Q1 2026), -$155.6 million (Q4 2025), and -$132.7 million (Q3 2025).